Last reviewed · How we verify
NCT05354128: RESCUE-STEMI
Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.
NA trial testing Thrombolytic in STEMI - ST Elevation Myocardial Infarction in 120 participants. Status unknown.
30 November 2022
Quick facts
| Lead sponsor | Ya-Wei Xu |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 April 2022 |
| Primary completion | 30 November 2022 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Thrombolytic — full drug profile →
- percutaneous coronary stenting
Conditions studied
- STEMI - ST Elevation Myocardial Infarction — all drugs for STEMI - ST Elevation Myocardial Infarction →
Sponsor
Ya-Wei Xu — full company profile →
Who can join
Adults 18 to 85, any sex, with STEMI - ST Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
During the outbreak of COVID-19, for patients with acute ST-segment elevation myocardial infarction with unclear infection, the time of primary PCI is uncertain, and it is often expected to exceed 90 minutes or even 120 minutes. In indicated patients, intravenous thrombolysis has significantly improved the recanalization time of criminal vessels.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05354128
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for STEMI - ST Elevation Myocardial Infarction
Currently open trials in the same condition.
- NCT07160491 — Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI · NA · recruiting
- NCT06013020 — Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus · Phase 4 · recruiting
- NCT06384846 — AI Algorithms in Prediction of ACS Based on Leukocyte Properties · recruiting
- NCT04436978 — What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? · Phase 4 · recruiting
- NCT05800951 — Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock · active not recruiting
Other Ya-Wei Xu trials
Trials by the same sponsor.
- NCT06690684 — Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases · enrolling by invitation
- NCT05935436 — Cardiac Shock Wave Therapy for the Treatment of Myocardial Infarction With Non-obstructive Coronary Arteries · NA · unknown
- NCT06385782 — Exploring HRV in Antarctic Overwintering Members of Asia · completed
- NCT03802929 — Diagnostic and Prognostic Prediction Models for Chinese Patients With Venous Thromboembolism · unknown
- NCT06698432 — SHR Predicts CMD in Patients with CCS · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05354128 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ya-Wei Xu
- Last refreshed: 26 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05354128.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing